Evidence map›Paper›PMID 39918684›Full record

ArticleDiabetes therapy : research, treatment and education of diabetes and related disorders2025

Correction to: The Long-Term Cost-Effectiveness of Tirzepatide 5 mg versus Dulaglutide 0.75 mg for the Treatment of People with Type 2 Diabetes in Japan.

Toshihiko Aranishi, Ataru Igarashi, Kazuo Hara, Beatrice Osumili, Zhihong Cai, Aska Mizogaki, Manaka Sato, Masakazu Takeuchi, Alice Minghetti, Barnaby Hunt and 1 more

Abstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in Diabetes therapy : research, treatment and education of diabetes and related disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors.

Toshihiko AranishiEli Lilly Japan K.K., 5-1-28 Isogami-dori, Chuo-Ku, Kobe, Japan.ORCID http://orcid.org/0000-0001-8862-9468
Ataru IgarashiDepartment of Health Policy and Public Health, Graduate School of Pharmaceutical Sciences, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 13-0033, Japan.ORCID http://orcid.org/0000-0001-6307-6916
Kazuo HaraDivision of Endocrinology and Metabolism, Department of Medicine, Jichi Medical University Saitama Medical Center, 1-847 Amanuma-cho, Omiya-ku, Saitama, 330-8503, Japan.
Beatrice OsumiliEli Lilly and Company Limited, 8 Arlington Square West, Downshire Way, Bracknell, RG12, 1PU, UK.ORCID http://orcid.org/0000-0002-5862-9325
Zhihong CaiEli Lilly Japan K.K., 5-1-28 Isogami-dori, Chuo-Ku, Kobe, Japan.ORCID http://orcid.org/0000-0002-3431-197X
Aska MizogakiEli Lilly Japan K.K., 5-1-28 Isogami-dori, Chuo-Ku, Kobe, Japan.
Manaka SatoEli Lilly Japan K.K., 5-1-28 Isogami-dori, Chuo-Ku, Kobe, Japan.ORCID http://orcid.org/0000-0001-7000-4769
Masakazu TakeuchiEli Lilly Japan K.K., 5-1-28 Isogami-dori, Chuo-Ku, Kobe, Japan.ORCID http://orcid.org/0000-0003-3176-3118
Alice MinghettiOssian Health Economics and Communications GmbH, Bäumleingasse 20, 4051, Basel, Switzerland.ORCID http://orcid.org/0000-0001-7913-5861
Barnaby HuntOssian Health Economics and Communications GmbH, Bäumleingasse 20, 4051, Basel, Switzerland. hunt@ossianconsulting.com.ORCID http://orcid.org/0000-0001-5420-279X
Takashi KadowakiToranomon Hospital, 2-2-2, Toranomon, Minato-ku, Tokyo, 105-8470, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID39918684
PMCPMC11867985

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.